StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

571 Study Matches

EA9161: A Randomized Phase III Study of the addition ofVenetoclax to Ibrutinib and Obinutuzumab versus Ibrutiniband Obinutuzumab in Untreated Younger Patients withChronic Lymphocytic Leukemia (CLL)

The is a drug study to compare the progression freesurvival of the three drug combination Ibrutinib-Obinutuzumab-Venetoclax (IOV) to Ibrutinib-Obinutuzumab (IO) in untreated CLL patients younger than 70 years of age.

pt will either get ibrutinib and obinutuzumab, plus venetoclax for up to 19 months or will get ibrutinib and obinutuzumab until doctor decides disease is getting worse or the side effects become too severe. After 19 cycles completed, doctor will follow condition every 90 days until progression and watch for side effects. They will check pt every 3 months for 2 years. After that, they will check pt every 6 months for 3 years. After that, they will check pt every 12 months for 5 years

Yes
 

Joseph Cioccio
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03701282
SITE00000485
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of CLL according to the NCI/IWCLL criteria or SLL according to the WHO criteria
Negative FISH analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy
Age ≥ 18 years and < 70.
ECOG performance status between 0-2.
Life expectancy of ≥ 12 months.

Exclusion Criteria:
No deletion of 17p13 on cytogenetic analysis by FISH
No active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic treatment.
No current use of corticosteroids.
No previous autoimmune complications
No other active primary malignancy
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Biobehavioral Health Risk and Resilience in College Students (PSU THRIVE Study)

This protocol is designed to examine biobehavioral health risks, resilience, grit, forgiveness and well-being in college students.

No
 

Laura Klein
Laura Klein - at lcklein@psu.edu or 814-883-8624
Biobehavioral Health (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00006962
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Fulltime undergraduate student
18 to 24 years of age
English is a primary language

Exclusion Criteria:
Not enrolled as a full time undergraduate student
Under age of 18 years
Over age of 24 years
Not comfortable speaking English
Mental & Behavioral Health
I'm interested
Share via email

Linking olfactory deficits to memory impairment and AD neurodegeneration

The purpose of this voluntary research study is to find out more about changes in the brain as we age. This study is trying to determine if magnetic resonance imaging (MRI), genetic variations, amyloid positron emissions tomography (PET), neuropsychological testing, and smell tests can be used to evaluate memory loss and cognitive impairment.

You will be asked to come to the research site once a year for 5 years.Annual (and semi-annual) procedures include completing smell tests, neuropsychological tests, magnetic resonance imaging (MRI). One-time procedures include provide blood sample, amyloid PET scan (if indicated), and optional lumbar puncture.

Up to $250 a year

Yes
 

Prasanna Karunanayaka
Rommy Elyan - at relyan@pennstatehealth.psu.edu
Radiology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00018557
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Individuals between ages 55-85

Exclusion Criteria:
Non-English speaking
Smell impairment
Women who are pregnant or breastfeeding
Currently smoke
Have claustrophobia
Neurology
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic hormone Sensitive Prostate Cancer (mHSPC)

The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC.

At the study visits, the following procedures should happen:• Your study eligibility will be determined• There will be a review of your current medications and medical history• You will undergo a physical examination that includes measuring your height, weight, taking your vital signs, checking your heart with an electrocardiogram, and determining your ECOG performance status (a measure of your daily functional activity)• You may undergo tumor biopsy if clinically feasible according to your doctor or may be asked for a previously collected sample. You will be asked for a previously collected tumor biopsy if clinically feasible by your doctor• Blood and urine will be taken to determine the function of your liver, kidneys, and bone marrow function.• Blood samples will also be collected to assess potential changes in biological molecules in the blood such as certain proteins and pieces of DNA shed from tumor cells • You will receive a variety of imaging procedures to determine the status of your cancer throughout the study. These will include CT and PET scans, bone scans and may include other scans like X-rays and MRI scans.• On repeat visits, your doctor will ask you about any changes in the way you feel

Yes
 

Monika Joshi
Kathleen Rizzo - at krizzo@pennstatehealth.psu.edu
Medicine: Hematology and Medical Oncology (HERSHEY)
 

Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04720157
STUDY00019697
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patients must have metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma (current or prior biopsy of the prostate and/or metastatic site)
Patients must have an ECOG performance status of 0 to 2
Patients must be adults >= 18 years of age
Patients must have evidence of PSMA-positive disease as seen on a 68Ga-PSMA-11 PET/CT scan

Exclusion Criteria:
Patients with rapidly progressing tumor that requires urgent exposure to taxane-based chemotherapy
Patients with CNS metastases that are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity
Patients with a history of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study
Patients with symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression
Patients who received transfusion for the sole purpose of making a subject eligible for study inclusion
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Graduate Students’ Experience with Online Professional Profiles and Social Media

With the development of information and communication technologies, Social Network Sites and other online platforms can be great resources for career-related information and social networking. Despite the evidence of possible professional benefits, it remains unclear whether graduate students’ experiences with building online career profiles and social networking are positive. Therefore, this study aims to understand graduate students’ experience with professional practices on the Internet concerning their motivations, benefits, and risks.

No
 

Chuhao Wu
Chuhao Wu - at cjw6297@psu.edu
Information Sciences and Technology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00019028
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
An active graduate student at University Park campus

Exclusion Criteria:
NA
Education
I'm interested
Share via email

Emotion Regulation and Mother-Infant Synchrony

The aim of this study is to better understand emotion regulation in infants by measuring brain, behavior, and mother-infant relational mechanisms. We plan to collect simultaneous brain activation in mothers and infants while they engage in a face-to-face interaction. We will then test associations between individual brain activation, mother-infant brain synchrony, and infant emotion regulation behaviors.

Participants complete questionnaires online, then come in for 1 in-person visit. Mother and baby complete a play and a neutral task while fNIRS is collected from them simultaneously.

40

Yes
 

Berenice Anaya
Berenice Anaya - at bua25@psu.edu
Psychology (UNIVERSITY PARK)
 

All
All
This study is also accepting healthy volunteers
STUDY00018109
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Infants who are 4 months and their mother.
Infants born 3 weeks within their due date.
Infants of a birth weight > 2500 g.
Infants with NO serious medical complications.
English-speaking families.

Exclusion Criteria:
Infants who were < 2500 g at birth.
Infants who experienced any serious medical complications.
Infants who were born > 3 weeks before the indicated gestational period.
Families who do not understand and do not speak English
Children's Health, Neurology
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Predicting Concussion Outcomes with Salivary miRNA

The purpose of this study is to identify changes in salivary micro ribosomal nucleic acid (miRNA) expression that are predictive of symptom duration and severity following mild traumatic brain injury (mTBI) in children. The primary endpoints of this study are as follows:1)Characterization of brain-related miRNA in the saliva of 250 children with mTBI and 200 age- and gender-matched controls between the ages of five and twenty-three years.2)Identification of a set of salivary miRNAs that is predictive of duration and severity of mTBI symptoms.

Saliva collection and surveys at baseline, 7 days, and 30 Days

$20

Yes
 

Jayson Loeffert
Brennen Harding - at bharding@pennstatehealth.psu.edu or 717-531-5656
Family and Community Medicine (HERSHEY)
 

All
All
This study is also accepting healthy volunteers
NCT02901821
STUDY00003729
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
5 to 23 years of age
Seen in the Penn State Pediatric Concussion Clinic within 2 weeks of most recent concussion

Exclusion Criteria:
Does not speak english
Periodontal disease
Ongoing seizure disorder, or other neurologic disorder
Drug or alcohol dependency
clinical diagnosis of severe TBI
Children's Health, Neurology, Sports Medicine
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI-22-063: NRG-GU011 NRG Promethean

This trial is comparing radiation therapy with or without hormone therapy in men with prostate cancer.

Patients must come in for all radiation treatments. Patients must take their androgen therapy as prescribed.

Yes
 

Joseph Miccio
psci-cto@pennstatehealth.psu.edu 717-531-5471
Radiation Oncology (HERSHEY)
 

Male
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05053152
SITE00001224
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pathologically (histologically or cytologically) proven diagnosis of prostate adenocarcinoma at any anatomical location (for example, prostate, metastatic site), including intraductal or ductal carcinoma, at any time before registration.
Age ≥ 18 years.
ECOG Performance Status 0-2 within 120 days prior to registration.
External beam and/or brachytherapy to: Prostate alone, prostate and seminal vesicles, prostate and pelvic nodes, or radiation to all three sites.
Radical prostatectomy alone, radical prostatectomy plus postoperative radiotherapy to the prostate bed, or radical prostatectomy plus postoperative radiotherapy to the pelvic nodes.

Exclusion Criteria:
Evidence of local tumor recurrence in the prostate and/or periprostatic/seminal vesicle region after radiotherapy, or in the prostate bed after prostatectomy.
Currently on androgen deprivation or anti-androgen therapy.
Osseous metastasis on 99mTc radionuclide bone scan
Extra pelvic nodal/soft tissue disease (> 1.5cm in short axis) on CT or MRI pelvis +/- abdomen
Spinal cord compression, or spinal intramedullary, brain, and/or visceral (for example liver, lung, etc.) metastasis
Cancer
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Imaging and Depression with or without MS

A study looking at the neural and genetic correlates of depression. Presently, the current study is looking to recruit individuals for two separate groups: 1. MS but NO history of depression2. Depression but NO history of MS or neurological disease. The purpose of the study is to look at patterns of brain structure and function in individuals with depression and compare them to those with MS. We will explore how any differences we find contribute to more problems with depression in MS and see how such differences might lead to better treatment options for depression.

Yes
 

Peter Arnett
Cristina Roman - at car342@psu.edu or 814-865-5578
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00006711
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between the ages of 30-65
Able and willing to undergo an MRI
Able to travel to State College for the Study

Exclusion Criteria:
Current psychotherapy treatment for depression
Started anti-depressant medication in the last 2 months
Diagnosis of bipolar disorder, schizophrenia, or significant neurocognitive impairment
Very severe depression that would interfere with the ability to participate or suicidal ideations
Unable to undergo an MRI (metal in your body)
Mental & Behavioral Health
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Postmenopausal women and their endothelium: Is dietary nitrate supplementation protective?

Heart disease is the leading cause of death in the United States. The loss of estrogen from menopause puts women at a greater risk of developing heart disease. The purpose of this study is to determine the effects of drinking beetroot juice on measures of blood vessel health and blood pressure. Participants will drink beetroot juice and placebo juice each for one week followed by blood pressure measurements and ultrasound imaging of an artery in the upper arm. A sub-aim of this study is to investigate the effects of estrogen status on blood vessel function between pre- and post-menopausal women.

There are a total of 6 in-person visits to the Clinical Research Center. You will be asked to drink beetroot juice (2 oz) every day for 7 days. Participants will undergo vascular assessments, blood pressure measurements, and blood draws (11 in total for 6 visits).

$120

Yes
 

David Proctor
Jocelyn Delgado - at jmd956@psu.edu or 408-679-8390
Kinesiology (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is also accepting healthy volunteers
NCT03644472
STUDY00010017
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Post-menopausal women (1-6 years since menopause preferred)
BMI <35
Blood pressure <130/80
LDL <170 mg/dL

Exclusion Criteria:
Individuals taking hormone therapy
Individuals with resting blood pressure > or = 130/80 mmHg
Users of any tobacco and/or nicotine products (smokers, chewing tobacco, nicotine-containing patches/gum, smokeless cigarettes)
Individuals with any overt cardiovascular, metabolic, hematologic, pulmonary, renal, musculoskeletal, and/or neurological disease(s)
Individuals with active cancer
Food & Nutrition, Heart & Vascular, Women's Health
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 2 locations

Study Locations

Hide all locations
Location Contacts
Altoona, PA ,
State College, PA ,

Slips of Action in Adolescents and Young Adults

Adolescence is a critical period during which many important healthhttps://irb.psu.edu/IRB/sd/ResourceAdministration/Project/ProjectEditor?Project=com.webridge.entity.Entity[OID[058ACDEB3E43384D816C7E390C2B83F6]]&amp;Mode=smartform&amp;WizardPageOID=com.webridge.entity.Entity[OID[E4552FC57E491543A6B7FD8268E23FD7]] habits form in humans. However, animal models provide mixed information about habit formation across development and there are relatively few human studies that address differences between habit formation in adolescents and adults. To address this gap, the proposed study will assess differences in habit formation in adolescents and adults as measured by the "Slips of Action" task, which seeks to discriminate between habitual and goal-directed learning of visual stimuli pairings.

There will be one in-person visit lasting about one hour. Visits will begin with informed consent. Participants will complete a computer task where they are asked to learn associations between pictures and then will be tested on the associated pairings. They will also complete questionnaires and cognitive tasks.

$20

Yes
 

Charles Geier
Katie Meeks - at kxm5964@psu.edu or 814-867-6472
Non-PSU Site
 

All
All
This study is also accepting healthy volunteers
STUDY00020521
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Healthy adolescents between the ages of 13 to 17; (health based on parental report)
Healthy adults between the ages of 25 to 40
No learning disabilities (e.g., ADHD) or diagnosed psychological conditions (e.g. anxiety)
Right handed
Not on any medications known to influence behavior

Exclusion Criteria:
Outside of age ranges specified at baseline
Diagnosed neurological or psychological condition including severe anxiety and/or depression, schizophrenia, learning disability, ADD/ADHD, or autism
Significant family history of neurological or psychological disorders
Left handed
Participant is on any medication that may influence behavior
Addiction & Substance Abuse, Food & Nutrition, Mental & Behavioral Health
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Reducing Perception Error in Diagnostic Radiology

This research is being done to find out the relationship between an individual’s mental state and how well they perform visual-perceptual tasks. This will allow us to understand the brain processes related to errors in image perception, to understand how mental states impact medical image interpretation. Overall, this research will help us develop training programs to reduce the amount of perceptual errors in diagnosing images

Yes
 

Michael Bruno
Lauren Spreen - at lspreen@pennstatehealth.psu.edu or 717-531-5857
Radiology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00007773
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Radiologists with different levels of experience
Healthy adults, with college or advanced degree
Normal or corrected to normal vision

Exclusion Criteria:
Non-English speaking
Pregnant or lactating
Presence of pacemaker, aneurysm clips, or any metal in the body
A history of welding or grinding
Claustraphobia
Education
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 22-141 CCTG MA.39: “Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

To compare the breast cancer recurrence-free interval (BCRFI) between patients that received regional RT or not, defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC.

Women with low risk breast cancer will be randomized to either regional radiation therapy or no regional breast radiation therapy. Patients will be expected to keep all of their radiation appointment and complete all questionnaires.

Yes
 

Leonard Tuanquin
PSCI CTO at PSCI-CTO@pennstatehealth.psu.edu
Radiology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03488693
SITE00001308
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patients must be women with newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases, staged as per site standard of care
Patients must have been treated by BCS or mastectomy with clear margins of excision*.
Patients with T3N0 disease are eligible.
Patients with disease limited to nodal micrometastases are eligible.
Patients must be ER ≥ 1% and HER2 negative on local testing

Exclusion Criteria:
Patients with nodal disease limited to isolated tumour cells
Patients with pT3N1 and pT4 disease
Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy
Synchronous or previous contralateral invasive breast cancer.
Patients who are pregnant.
Cancer
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Endometriosis and microvascular dysfunction

Endometriosis, is a disorder that occurs in women, is when tissue that should be normally found inside the womb is also found in sites outside of the womb. This disorder impairs the function of the endothelium, the cells that line the body’s blood vessels (endothelium). The endothelium helps to control blood flow in healthy vessels. Women with this disorder not only have an increased risk for high blood pressure and high cholesterol, they also have an increased risk for cardiovascular disease. They have a higher risk for cardiovascular disease, too. With this study, we will learn how endometriosis impairs the lining of blood vessels and increases the risk for disease. We will test two different intervention strategies to reduce long-term cardiovascular disease risk in women with endometriosis.

There will be 3 in person visits, blood draws will occur at all visits. On 2 of the visits blood flow experiments will be conducted. Participants will take oral medications.

390

Yes
 

Lacy Alexander
Susan Slimak - at sks31@psu.edu or 814-863-8556
Kinesiology (UNIVERSITY PARK)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05059626
STUDY00018347
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Women, 18-45 years of age
Endometriosis

Exclusion Criteria:
Tobacco consumption (e.g. smoking)
Pregnant and/or breastfeeding
Taking blood pressure medication
Heart & Vascular, Pregnancy & Infertility, Women's Health
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 5 locations

Study Locations

Hide all locations
Location Contacts
Altoona, PA ,
Harrisburg, PA ,
Hershey, PA ,
State College, PA ,
Williamsport, PA ,

REGIMEN-SPECIFIC APPENDIX FFOR ABBV-CLS-7262

We are doing this research to find out if ABBV-CLS-7262 can help with Amyotrophic Lateral Sclerosis (ALS). We also want to find out if ABBV-CLS-7262 is safe to take without causing too many side effects.

•Ask you to complete questionnaires about your general health and well-being [Baseline Visit and Weeks 4, 8, 16 and 24/Early Termination (ET) Visits] •Collect a blood sample for:oTesting the amount of study drug in your body [Weeks 4, 8, 16, and 24/ET]oTest certain hormone levels [Regimen Screening, Week 4, 16, and 24/ET]oTest for a bleeding disorder prior to lumbar puncture [Regimen Screening if not done at Master Protocol Screening Visit, Week 16] oBiomarker (including RNA) testing [Baseline Visit, Week 8, 16, and 24/ET]oOver the course of the placebo-controlled portion of this research study, total blood draw volume for the samples listed above will be approximately 32mL or 2 tablespoons per visit •Collect a urine sample for:oRoutine safety testing [Baseline Visit, Week 4, Week 8, 16, and 24/ET]oBiomarker testing [Baseline Visit, Week 8, 16, and 24/ET]•Collect electrocardiogram (ECG) to assess for cardiovascular safety [Baseline Visit, Week 8, 16, and 24/ET]•Collect your vital signs (blood pressure, breathing &amp; heart rate, blood oxygen level, and temperature)•Perform a lumbar Puncture to collect spinal fluid [Baseline and Week 24 Visit]•If you are a woman of childbearing potential, you will be asked to complete a Menstrual Cycle Questionnaire throughout the duration of this regimen

You will receive payment for the following: 1.stipend of $50 per on-site visit; 2.stipend of $100 per lumbar puncture (LP requested Weeks 28 and 52); 3.reimbursement for travel of $65 per on-site visit.

Yes
 

Zachary Simmons
nervemuscle@pennstatehealth.psu.edu 717-531-8257
Neurology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05740813
SITE00001309
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite ALS defined by revised El Escorial criteria
Age 18 years or older
Capable of providing informed consent and complying with study procedures, in the SI’s opinion
Time since onset of weakness due to ALS ≤ 36 months at the time of the Master Protocol Screening Visit

Exclusion Criteria:
Use of any moderate or strong CYP3A4 inhibitor or inducer within 10 days or 5 half- lives (whichever is longer) prior to Baseline and throughout the study
Abnormal adrenal function, defined as confirmed abnormal random cortisol (<5 μg/dL) or ACTH (>2x upper limit of normal) at Regimen Specific Screening.
Any clinically significant ECG abnormalities, including QT interval corrected for heart rate using Fridericia’s correction formula (QTcF) of > 450 msec for males or > 470 msec for females at Master Protocol Screening.
Neurology
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Evaluation of the Immune Response and Antigenic Signature of Patients with Babesia Infection in Pennsylvania with the Aim of Developing a Rapid Diagnostic Test

We are evaluating patients who have been infected with Babesia. Babesia is a blood parasite that is acquired from ticks. The number of cases seen in Pennsylvania every year has been increasing. We intend to evaluate the blood of patients acutely infected with Babesiosis and review for possible simultaneous co-infections. We will compare those infected patients with the blood of healthy individuals. The goal is to identify proteins in the blood of acutely infected patients that are specific for Babesia and also evaluate the prevalence of patient's who have contracted a co-infection from the tick vector that transmitted the Babesia infection. The identification of the specific bacterial/parasitic antigens could then be used to create rapid diagnostic tests and help clinicians increase awareness of these tick-borne diseases.

We will obtain basic demographic information and past medical history. We will obtain two 10ml samples of blood. The blood will then be stored and ultimately sent to Antigen Discovery, Inc for proteomic array screening.

Yes
 

DAVID INGRAM
David Ingram - at dingram@pennstatehealth.psu.edu or 717-531-8881
Medicine: General Internal Medicine (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00011530
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Healthy
18 years or older

Exclusion Criteria:
Active Cancer
History of having your spleen removed
History of liver or kidney disease
HIV
Diabetes
Infectious Diseases & Immune System
I'm interested
Share via email
Show 3 locations

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,
Reading, PA ,
Wilkes-Barre/Scranton Area, PA ,

A151216-Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (Alchemist)

Purpose of study is to examine lung cancer patients' surgically removed tumors for certain genetic changes and to possibly refer these patients to a treatment study with drugs that may specifically these tumors.

Patients will be registered to the trial after surgical intervention. One vial of peripheral blood and a tissue block (or scrolls) will be submitted to the study. Once testing is completed, subject is notified if they are eligible for one of the sub protocols.

Yes
 

Marc Rovito
Michelle Eschbach - at meschbach@pennstatehealth.psu.edu or 610-378-2336
Cancer Institute (ST. JOSEPH)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02194738
AFFIL0A151216
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Surgically resected non-small cell lung cancer
Pathologic stage IIIA, II (IIA or IIB) or large IB (defined as size ≥4 cm).
Tissue available for the required analyses

Exclusion Criteria:
No patients with recurrence of lung cancer after prior resection
No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD1/PD-L1/CTLA-4.
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Reading, PA ,

Perception of English sentences in context

This study tracks the eye movements of 30 adults to gather information on how they process sentences when presented in a context.

Yes
 

Frances Blanchette
Frances Blanchette - at fkb1@psu.edu or 814-863-7392
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00007476
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
adult (18+)
native speaker of American English
grew up mainly in the US

Exclusion Criteria:
under 18 years of age
not a native speaker of American English
did not grow up mainly in the US
Language & Linguistics
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Comparison of Two Methods of Genre-based (Research Article) Writing Instruction

The different effects of genre-based writing instruction and integration of technology use in genre-based writing instruction will be examined. The specific genre for this study is a research paper. Different patterns of instructor-learner interaction in both instructional situations will also be investigated.

There will be three in-person visits for instructions on academic writing. Pre- and Post-instructions questionnaires and reflective journals will be collected.

Yes
 

Minjin Kim
Minjin Kim - at mmk6337@psu.edu or 814-883-1023
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00019764
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
master's students
non-native English speakers
adults older than 18 years old
active student enrolled at University Park campus
living in the United States

Exclusion Criteria:
native English speakers
younger than 18 years old
not living in the United States
Education, Language & Linguistics
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Telehealth Navigation for Informed Prostate Cancer Screening in Black Men

This study is being conducted to determine whether patient navigation improves informed decision making for prostate cancer screening. Participants will be offered the opportunity to discuss and address issues related to PSA testing with a patient navigator over a one month period. Surveys at the beginning and end of this period will include health knowledge, opinions on telehealth, and barriers to health care. All sessions will be conducted virtually.

Complete short on-line questionnairesComplete at least one telehealth session with the Patient Navigator

100

No
 

Joshua Muscat
Chrispin Bandakulu - at ckayembebandakulu@pennstatehealth.psu.edu or 717-531-5274
Public Health Sciences (HERSHEY)
 

Male
18 year(s) or older
This study is also accepting healthy volunteers
NCT00000000
STUDY00019025
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
black men
ages 45 to 70
spoken english language

Exclusion Criteria:
history of prostate cancer
Men's Health, Prevention, Cancer
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov

ATHN 10: Leveraging the ATHNdataset to Document the State of RareCoagulation Disorders in the United States

This is a multi-center project in which the American Thrombosis &amp; Hemostasis Network (ATHN) will offer free genotyping to individuals with Rare Coagulation Disorders (RCD).

One tube of blood will be collected during a routine clinic visit.

Yes
 

M. Elaine Eyster
Lisa Baker - at lbaker@pennstatehealth.psu.edu or 717-531-7468
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
SITE00000669
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Subject must have an established Rare Coagulation Disorder diagnosis (
Must currently receive or have received care at and ATHN affiliated HTC
Subject must have opted into the ATHNdataset

Exclusion Criteria:
Subject is unwilling to sign informed consent form
Blood Disorders
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Understanding experiences of international students with healthcare and antibiotics

This study examines the experiences of international students with regard to upper respiratory illnesses, healthcare, and use of antibiotics in their home countries and in the United States. The findings of the study will inform the development of training to improve healthcare providers’ communication skills for discussing antibiotics with international students.

Complete one online survey, which takes approximately 20 minutes.

10.00

No
 

Erina Farrell
Erina Farrell - at elm26@psu.edu
Communication Arts and Sciences (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00021922
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years of age or older
College/university undergraduate or graduate student at a U.S. university
born and raised in and is currently a citizen of China, India, or South Korea
English speaking
lived in the United States for less than 7 years

Exclusion Criteria:
Less than 18 years of age
Not a college or university student at a U.S. university
Not born or raised in and currently citizen of China, India, or South Korea
Not English speaking
Lived in the United States more than 7 years
Infectious Diseases & Immune System
Not applicable
I'm interested
Share via email

Predicting Ipsilesional Motor Deficits in Stroke with Dynamic Dominance Model

This study will test the hypothesize that the combination of low-moderate to severe paresis and persistent motor deficits in the non-paretic arm limits functional independence in chronic stroke survivors. We, therefore, predict that intense remediation, focused on improving the speed, coordination, and accuracy of the less-impaired arm should improve functional independence.

There will be two evaluation sessions, 15 training sessions, and 3 post-test evaluation sessions

$2,100

Yes
 

Robert Sainburg
Candice Maenza - at CMaenza@psu.edu or 717-531-0003, ext=283146
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03634397
STUDY00008385
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Over the age of 18
Motor impairment in the arm
Had a stroke confirmed by neurology
Chronic stage of stroke

Exclusion Criteria:
neurological disease other than stroke
a major psychiatric diagnosis (e.g., schizophrenia, major affective disorder)
hospital admission for substance abuse
peripheral disorders affecting sensation or movement of the arms,
currently taking prescription drugs with known sedative properties that interfere with sensory-motor function
Neurology
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A PHASE III, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, NON-INFERIORITY, MULTI-CENTER STUDY OF THE EFFECTS OF STOPPING HYDROXYCHLOROQUINE IN ELDERLY LUPUS DISEASE

This trial will address the safety of withdrawing hydroxychloroquine (HCQ) in patients with systemic lupus erythematous who are 60 years of age or older. In this older population the benefits of HCQ are expected to decrease since disease activity decreases with advancing age. The study will test whether HCQ can be safely discontinued in stable/quiescent patients.

Participants will be in this study for about 1 year, during which time they will come to 7 visits in the research clinic. The first visit will take up to 2 hours and will include blood and urine sampling and completion of self-assessment questionnaires. Subsequent visits will take up to 1 hour. Participants will be randomized to receive either the active drug hydroxychloroquine or placebo. The treatment will be blinded to both the participant and the investigator. Diaries will be requested in which the participant keeps track of dosing of the study medication.

Yes
 

Nancy Olsen
Jamie Carter - at jcarter3@pennstatehealth.psu.edu or 717-531-4921
Medicine: Rheumatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05799378
SITE00001380
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Have a diagnosis of systemic lupus
Be treated with hydroxychloroquine for at least 7 years
60 years of age or older
stable disease without recent flares

Exclusion Criteria:
abnormal eye exam related to use of hydroxychloroquine
taking more than 5 mg/day prednisone
any signs of active lupus disease.
Infectious Diseases & Immune System, Arthritis & Rheumatic Diseases
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Effects of heating on exercise pressor reflex in peripheral artery disease: Exercise Ability

To determine if the sympathetic and blood pressure (BP) responses to exercise will be attenuated during and after heat exposure in patients with peripheral artery disease (PAD).

There will be up to 6 visits at the Hershey Medical Center.The visits involve walking on a treadmill, sitting in a warm or neutral temperature bath, wearing a heat suit, and having one or both of your legs in a warm bath.

You will receive $25 per hour for your participation in this research study

Yes
 

Jian Cui
Cheryl Blaha - at cblaha@pennstatehealth.psu.edu or 717-531-1605
Heart and Vascular Institute (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00005798
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
healthy females and males
all minorities and ethnicies included
free of acute or chronic medical conditions
over 21 years old

Exclusion Criteria:
Females who are pregnant or lactating
under 21 years old
Decisional impairment
Heart & Vascular
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 21-160: A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia

The purpose of the study is to evaluate the potential interaction between ASTX727 and venetoclax, the study drugs, evaluate the safety when the study drugs are taken together, and any potential benefits of taking the study drugs together.

The study is expected to last about 20 months. The amount of time you will be on study treatment or be followed up for health information as part of the study depends on how you respond to and tolerate the study treatment.Study assessments/procedures will occur during screening, a period in which your eligibility to enter the study is determined, while on treatment, at treatment discontinuation, when you decide to or are taken off the study treatment, and during the safety follow-up period. While in the study you must follow the directions given to you by the study staff. If you do not follow the directions given to you, you may not be able to continue taking part in the study. You must come to the study center for all visits, including the follow-up visit after your last dose of study treatment, unless you are told a telephone call is an acceptable option.

Yes
 

Hong Zheng
Kelly Hansard - at khansard@pennstatehealth.psu.edu or 717-531-3716
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04657081
STUDY00019518
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Participant must be 18 years of age or older.
Newly diagnosed AML by World Health Organization (WHO) 2016 criteria
For Phase 1, ECOG 0-2. For Phase 2, ECOG 0-3.
Projected life expectancy of at least 3 months.

Exclusion Criteria:
Known active central nervous system involvement from AML.
Known active hepatitis B or C infection
Known human immunodeficiency virus (HIV) infection
Severe renal impairment
Cancer
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Califormula Study: Calibrated Formula Feeding to Optimize Infant Growth

This pilot study seeks to determine if formula feeding recommendations that are adjusted using age and weight specific caloric intake recommendations can prevent excessive infant weight gain and reduce overweight in the first 6 months after birth among infants born to mothers with overweight prior to pregnancy electing to exclusively formula feed their infants.

There will be 5-7 visits, where you will record formula volumes on diary cards for a total of 6 days per visit, and be given formula volume recommendations if you are in the intervention group. All participants will complete surveys when their infants are 1 and 6 months of age.

$300

Yes
 

Ian Paul
Courtney Byrnes - at cbyrnes@pennstatehealth.psu.edu or 717-531-0003, ext=322458
Pediatrics: General Pediatrics (HERSHEY)
 

All
Younger than 18 years old
This study is also accepting healthy volunteers
NCT05104073
STUDY00018788
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Formula-fed infants
Term or Early term Infants (≥37 weeks)
Infant birthweight ≥50th percentile

Exclusion Criteria:
Infants who weigh less than their birthweight between 14-21 days after delivery
Children's Health, Food & Nutrition
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Normalizing preteen HPV vaccination with practice-based communication strategies (Protect Them)

This study seeks to adapt and test a culturally-relevant, web-based game intervention to motivate Spanish-speaking preteens to initiate and complete human papillomavirus (HPV) vaccination. The present study will adapt an existing web-based game developed as an educational tool on HPV vaccination for English-speaking preteens in North Carolina. The study includes the recruitment of paired dyads (Spanish-speaking preteens and parents) to focus groups to evaluate the acceptability of cultural adaptations to the existing web-based game intervention. We will recruit up to 25 parents and preteens ages 11-12 who will receive a link to the Spanish game to play for 7-10 days in advance of the focus group discussions. The focus groups will ask participants about cultural and language adaptations to the existing game and how they react to a game that will serve as an interactive, educational tool on HPV vaccination. The focus groups will take place in Harrisburg, PA between January and March of 2018. No health information will be collected as part of this study.

Yes
 

William Calo
William Calo - at wcalo@phs.psu.edu or 717-531-3535
Public Health Sciences (HERSHEY)
 

All
All
This study is also accepting healthy volunteers
SITE00000339
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pretens 11 or 12 years old
Not vaccinated with the HPV vaccine
Have computer, tablet, or smartphone

Exclusion Criteria:
Having received the HPV vaccine
Children's Health, Prevention
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Harrisburg, PA ,

CC-93538-EE-001 – A PHASE 3, MULTI-CENTER, MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION AND MAINTENANCE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS

The scope of the study is to use a novel biologic drug, CC-93538, against symptoms of esophageal dysfunction and inflammation in subjects with Eosinophilic esophagitis (EoE).The CC-93538 will target the IL-13 receptor, a key driver of disease pathology in EoE. The phase 3 program will evaluate the safety and efficacy of CC-93538 in placebo-controlled Induction, Maintenance, and Open-Label Extension study.

The participants are required to sign the consent form. If you decide to participate, you will be required to attend study visits, follow doctor's instructions and take the study drug as instructed. You will be required to complete electronic questionnsires, and tell you doctor about any health problems, symptoms and drugs that you are taking. There are two visits during screening, including EGD procedure with biopsies. All the procedures during screening are done to determine if you are qualified to participate in the study. If the screening tests show that you can take part in this study, a computer program will make the assignment of which study drug you are to receive. You will be assigned to start the study by receiving either active drug (360 mg of CC-93538), or placebo. Both active drug and placebo will be given weekly by subcutaneous injection.You will be asked to have blood test done for serum and for biomarkers at most of your visits (except week 20). Physical exam and pregnancy's tests will be done at screening visit, and every visit during the induction after week 4. the ECG test will be done at screening. Similarly, the blood work and pregnancy's tests will be done at every visit during the maintenance. urinalysis and physical exam will also be done at some visits in the maintenance. Your vital signs will be monitored throughout the study.

$750 induction, $565 Maintenance max

Yes
 

Kofi Clarke
Zvjezdana "Stella" Chroneos - at zchroneos1@pennstatehealth.psu.edu or 717-531-0003, ext=322136
Medicine: Gastroenterology and Hepatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04753697
STUDY00017625
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults with body weight more than 40 kg
Histologic evidence of EoE
Symptoms of dysphagia
Previous therapy with PPI medications, intolerant or inadequate corticosteroid response, or steroid responders/naive
Must agree to maintain stable diet

Exclusion Criteria:
Active, ongoing infections
Liver function impairment, structural abnormality of esophagus
Receiving concurrent treatment with another IP, or the same drug previously
Currently is succesfully treated for EoE with dietary modifications
Currently receiving corticosteroids
Digestive Systems & Liver Disease
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Children’s reaction to multimodal cues in instructional materials

We aim to study how minoritized students perceive multimodal cues in instructional materials to improve STEM teaching for their STEM identity development.

To participate in the study at Penn State, students will be accompanied with their parent or a legal guardian. During the 40-minute session, participants will be asked to complete a brief survey and take part in an interview.

$50

Yes
 

Chanmin Kim
ChanMin Kim - at cmk604@psu.edu or 814-865-9919
Learning and Performance Systems (UNIVERSITY PARK)
 

All
Younger than 18 years old
This study is also accepting healthy volunteers
STUDY00022788
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Racially and/or ethnically minoritized students among 2nd through 5th graders
English is understood by prospective subjects or representatives

Exclusion Criteria:
Not racially and/or ethnically minoritized students among 2nd through 5th graders
English is not understood by prospective subjects or representatives
Education
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,